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Abstract
Background: There exists considerable debate concerning management of prosthetic vascular graft infection
(PVGI), especially in terms of antimicrobial treatment. This report studies factors associated with treatment failure in
a cohort of patients with staphylococcal PVGI, along with the impact of rifampin (RIF).
Methods: All data on patients with PVGI between 2006 and 2010 were reviewed. Cure was defined as the absence
of evidence of infection during the entire post-treatment follow-up for a minimum of one year. Failure was defined
as any other outcome.
Results: 84 patients (72 M/12 F, median age 64.5 ± 11 y) with diabetes mellitus (n = 25), obesity (n = 48), coronary
artery disease (n = 48), renal failure (n = 24) or COPD (n = 22) were treated for PVGI (median follow-up was 470 ±
469 d). PVGI was primarily intracavitary (n = 47). Staphylococcus aureus (n = 65; including 17 methicillin-resistant S.
aureus) and coagulase-negative Staphylocococcus (n = 22) were identified. Surgical treatment was performed in 71
patients. In univariate analysis, significant risk factors associated with failure were renal failure (p = 0.04), aortic
aneurysm (p = 0.03), fever (p = 0.009), aneurysm disruption (p = 0.02), septic shock in the peri-operative period
(p = 0.005) and antibiotic treatment containing RIF (p = 0.03). In multivariate analysis, 2 variables were
independently associated with failure:septic shock [OR 4.98: CI 95% 1.45-16.99; p=0.01] and antibiotic containing
rifampin [OR: 0.32: CI95% 0.10-0.96; p=0.04].
Conclusion: Results of the present study suggest that fever, septic shock and non-use of antibiotic treatment
containing RIF are associated with poor outcome.
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Background
Prosthetic vascular graft infections (PVGI) are uncom-
mon and severe, and are associated with high mortality
and morbidity [1-3]. Staphylococcus species are most
commonly associated with PVGI, regardless of the onset
(early or late) and localization of the PVGI. Up until
now, there has been an absence of evaluation of medical
treatment in terms of patient outcome. Most studies
reported in the literature were limited by their small
population size and non-uniform microbiological criteria
for defining infection. Fitzgerald et al. [1] and other
authors [4-6] suggested 6-week intravenous treatment
following oral treatment, for a total of 6 months (or,
for certain selected patients, their entire lifetime). In
addition, details on antimicrobial agents used, their
route of administration and their duration were not
mentioned in most published studies [7-12]. Antimicro-
bial agents with bactericidal properties and activities
against biofilm, such as rifampin (RIF), were of interest
in PVGI [13,14], as reported in treatment of prosthetic
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valve infective endocarditis [15-18] and prosthetic joint
infection [19-22].
The role of RIF in systemic antimicrobial therapy for
staphylococcal PVGI has not been previously assessed in
clinical studies. The aims of this study were therefore to
identify factors associated with treatment failure in a co-
hort of patients with staphylococcal PVGI, and to assess
the impact of RIF in systemic antibiotic therapy adminis-
tered to these patients.
Methods
Study design
This was a prospective study of an observational cohort
of 84 from 200 patients admitted at two French refer-
ence centers for PVGI and treated for staphylococcal
PVGI. Results were reported for 84 selected patients
which were followed-up for a minimum of one year after
the end of treatment in cases of graft implantation
(3 months in cases of removal of graft). We compared
characteristics of patients according to outcome.
Ethics committee
This study was approved by the institutional review
boards of both Dron and university of Lille Hospitals, in-
cluding the use of the data’s patients for publication. All
patients included in this study were informed and gave
their consent to the medical and surgical treatment.
Their consent was drawn in the medical record.
Study population
All patients treated from 2006 to 2010 for PVGI due to
Staphylococcus spp. were identified in our database of
200 patients, by searching for “Staphylococcus aureus”
and “coagulase-negative staphylococci (CNS)”. Ninety-
one patients were selected based on microbial results
and the delay of follow-up (> one year of follow-up after
the end of treatment). Seven were excluded due to ab-
sence of data on medical treatment or insufficient
follow-up.
Definition of PVGI
We used the same definitions as in previous studies
from our group [3,23] which were derived from those
proposed by Fitzgerald et al.[1].
Definite PVGI
A patient was considered as having definite PVGI if at
least two of the three following criteria were present: (i)
positive bacterial culture of intraoperative specimens or
blood samples (for potentially contaminating bacteria
such as CNS, Propionibacterium acnes and corynebac-
teria, at least two intraoperative specimens or blood
samples, or at least one intraoperative specimen and one
blood culture, were required); (ii) clinical signs of
infection [general (fever, chills, septic shock) or in the
area of the prosthesis (e.g. inflammatory signs in the area
of the vascular graft: local pain, erythema or tumefac-
tion, sinus tract infection communicating with PVGI,
enteric aortic fistula, intraoperative gross purulence or
failure of graft consolidation]; (iii) biological signs of
infection (C-reactive protein > 10 mg/L, white blood
count > 10 G/L) or other radiological signs of infection
(perigraft air or fluid persisting for more than 8 weeks
postoperatively, abscess contiguous to the implant). Each
case of definite infection was classified as early-onset in-
fection (i.e. occurring within 4 months after surgery) or
as late-onset infection (i.e. occurring more than 4 months
after surgery).
Presumed PVGI
PVGIs infections were suspected when bacteremia re-
lated to a site other than the surgical site occurred
within 4 weeks after graft implantation) [24,25].
“Onset of PVGI” was defined as time from implant-
ation of the prosthesis to clinical onset of infection and
was categorized into early (< 4 months after the implant-
ation) or late (≥ 4 months after the implantation) PVGI.
Microbiological documentation
Blood specimens for culture were drawn from all febrile
patients. Superficial samples were not used. Antibiotic
susceptibility patterns were interpreted in accordance with
recommendations from the Comité de l’Antibiogramme
de la Société Française de Microbiologie (http://www.
sfm-microbiologie.org/UserFiles/files/casfm_2003.pdf).
Risk factors for PVGI
Diabetes mellitus was defined according to the inter-
national classification [26]; chronic obstructive pulmon-
ary disease (COPD) as per the American Thoracic
Society [27]; obesity as body mass index (BMI) ≥30 kg/m2
and overweight as 25 ≤ BMI < 30 kg/m2; malnutrition
as ≤19 kg/m2 [28]; chronic renal failure according to
the value of creatinine clearance determined by the
Cockroft-Gault equation [29]; and immunodepression
(e.g. steroid therapy > 7.5 mg per day, cancer, AIDS).
Medical and surgical management
Empirical antibiotic treatment
Empirical treatment was started immediately after micro-
biological intraoperative samples were taken in patients
without severe sepsis and consisted of a combination of
broad-spectrum beta-lactams (i.e. piperacillin-tazobactam,
cefepim-metronidazole, etc.) and anti-methicillin-resistant
S. aureus (MRSA) agents (i.e. vancomycin, daptomycin, li-
nezolid) ± aminoglycosides. For patients with severe sepsis
or septic shock, this empirical treatment regimen was
started before surgery. No antibioprophylaxis was given
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before surgical revision. Empiric postoperative antibiotic
therapy was defined as adequate if it contained ≥ 1 anti-
biotic agent active against the pathogen(s) identified in in-
traoperative or blood cultures.
Definite antibiotic treatment
Empirical antibiotic treatment was de-escalated as soon
as the susceptibility of microbial agents was available,
and included RIF according to the antibiotic susceptibil-
ity profile of the staphylococcal strains. The daily dose of
RIF was 20 mg/kg divided into two doses, without ex-
ceeding 1,800 mg/day, initially by the intravenous route
(5–7 days) and then by oral administration.
Total duration was 3 weeks in case of removal with or
without replacement of the implants. For allo/homo-
grafts and prosthetic grafts, total duration was 6 months
(including 6 weeks intravenously), and in some cases,
was prolonged in the form of suppressive therapy using,
in most cases, oral doxycycline once daily at the discre-
tion of infectious physicians.
Surgical treatment
For us, the optimal surgical option was complete de-
bridement of devitalized and infected tissues around the
prosthesis, total graft excision and in situ reconstruction
with a new prosthesis, autogenous vein or arterial allo-
graft/homograft. Debridement without graft excision was
proposed in patients with very early PVGI or in patients
with severe co-morbidities. Finally, when revasculariza-
tion was not possible, amputation was proposed to the
patient.
Outcome
Remission was defined as the absence of local or sys-
temic signs of infection assessed during the most recent
contact with the patient, along with absence of the need
to re-operate or to administer antibiotic therapy directed
to the initial infected site, from the end of treatment to
the most recent contact. Failure was defined as any other
outcome, including new surgery for infection or death
related to PVGI during follow-up. Results were reported
for patients within a minimum follow-up of 3 months in
case of removal of PVGI with venous graft, or within
one year for the other cases. In cases of suppressive ther-
apy, we consider a patient in “remission group” if there
is no clinical, radiological or biological specific signs of
PVGI after one year of follow-up after its theoretical end
of treatment.
Statistical analysis
χ2-test was used to compare qualitative variables and a
2-sample t test to compare continuous variables. A p-
value < 0.05 was considered a significant difference.
To determine independent variables associated with
outcome, we performed a complete multivariate analysis
including prognostic factors associated with P value < 0.10
in bivariate analysis and, if clinically relevant, some forced
variables. Then, adjusted ORs were computed with a lo-
gistic regression analysis. To compare the survival distri-
bution of the two samples, we used the log rank test to
assess the validity of the model. Statistical analysis was
performed using STATAV7.
Results
Eighty-four patients (72 males and 12 females; median
age: 64.5 ± 11.4 years) were treated for presumed [n = 8
(9.5%)] or definite PVGI [n = 76 (81.5%)], including 42
early cases and 34 late cases with a median follow-up of
470 ± 469 days. The main characteristics of patients are
listed in Table 1 and Table 2. The localization of PVGI
was intracavitary or extracavitary (femoro-femoral or
femoropopliteal vascular graft) in 47 and 37 patients,
respectively.
Initial indications for vascular prosthetic implantation
included aortic aneurysms (n = 32; 38.1%) and/or periph-
eral artery disease (n = 65; 77.3%). At admission, clinical
signs suggesting an infectious process involving the pros-
thetic vascular graft were: fever > 38°C [n = 56 (66.6%)],
wound erythema [n = 57] (67.8%) and drainage |n = 55
(65.5%)], abdominal discomfort [n = 17 (20.2%)] and
gastro-intestinal bleeding [n = 1 (1.1%)]. Mean values
of white blood cell count and C-reactive protein were
11.141 ± 4.282 G/L, and 108 ± 106 mg/L, respectively.
The main radiological signs associated with these clin-
ical and biological abnormalities were perigraft air or
fluid persisting for more than 8 weeks postoperatively
[n = 69 (82.1%)], recent graft occlusion [n = 11 (13.1%)],
free or contained disrupted anastomoses [n = 9 (10.7%)]
and false aneurysm [n = 11 (13.1%)]. Staphylococcal PVGI
was mainly intracavitary (i.e. involving the intra-abdominal
or intrathoracic portion of the graft [n = 47 (55.9%)]. Mean
delays from implantation to diagnosis of PVGI were
692 days and 620 days in the remission and failure groups,
respectively (p = 0.83).
Microbiological documentation was obtained for all
patients (Table 3). A total of 114 causative microorgan-
isms were isolated: S aureus (n = 65; including 17
MRSA), CNS (n = 22), Gram-negative bacilli (n = 14), an-
aerobes (n = 3), Candida spp. (n = 4) and other (n = 6). A
total of 21 (25%) patients had polymicrobial infections.
Three of them patients had polymicrobial staphylococcal
infection. Thirty-six patients (42.8%) had concomitant
bacteraemia. In 15 patients (17.8%), blood culture was
the only positive microbiological documentation. Forty-
seven patients (55.9%) had positive bacterial culture of
intraoperative samples. In 21 patients (25%), both blood
and intraoperative culture were positive. Finally, in 2 pa-
tients (2.3%), the causative agent was obtained from
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culture of abscess puncture. Surgical treatment was per-
formed in 71 patients (84.5%) (Table 1, Figure 1.).
The empirical antimicrobial treatment was vanco-
mycin (n = 39), teicoplanin (n = 11), daptomycin (n = 13),
linezolid (n = 5) or others (n = 16) in addition to broad
spectrum betalactams ± aminoglycosides. The empirical
treatment was considered as adequate in 79 patients.
The definite antimicrobial treatment was as follow: 45
patients were treated with RIF combinations including
RIF-fluoroquinolone (n = 24), RIF-cotrimoxazole (n = 8),
RIF-flucloxacillin (n = 4), cotrimoxazole-RIF-fluoroquinolone
(n = 2), RIF-daptomycin (n = 1), RIF-fluoroquinolone-li
nezolid (n = 1), RIF-teicoplanin (n = 1), RIF-fluoroquin
olone-imipenem (n = 1), RIF-fucidic acid (n = 1), RIF-fl
uoroquinolone-fluconazole (n = 1), RIF-cotrimoxazole-
ceftriaxone (n = 1). The 39 others patients were treat
ed either with combinations including fluoroquinolone
combinations [cefazolin-fluoroquinolone (n = 8), clinda
mycin-fluoroquinolone (n = 5), flucloxacillin-fluoroqui
nolone (n = 2), pristinamycin-fluoroquinolone (n = 1),
teicoplanin-fluoroquinolone (n = 1), fucidic acid-fluoro
quinolone (n = 1), imipenem-fluoroquinolone (n = 2),],
Table 1 Demographic characteristics of 84 patients with staphylococcal PVGI
Population, n = 84 Remission Failure p
n = 63, (%) n = 21, (%)
Age, mean ± SD 64.1 ± 11 67.8 ± 12 0.2
Diabetes mellitus 19 (30.1) 6 (28.5) 0.89
Body mass index, mean ± SD 25 ± 4.7 26 ± 4.3 0.46
Creatinine clearance < 60 ml/min 15 (23.8) 9 (42.8) 0.09
Immunodepression 11 (17.4) 4 (19.1) 0.86
Chronic obstructive pulmonary disease 14 (22.2) 8 (38.1) 0.15
Coronary disease 35 (55.5) 13 (61.9) 0.61
Aortic aneurysm 20 (31.7) 12 (57.1) 0.03
Presumed PVGI 7 (11.1) 1 (4.7) 0.39
Definite PVGI 56 (88.9) 20 (95.2) 0.39
Early definite PVGI (<4 months) 30 (47.6) 12 (57.1) 0.45
Late definite PVGI (> 4 months) 26 (41.2) 8 (38.1) 0.79
Extracavitary PVGI 31 (49.9) 6 (29.6) 0.07
Fever > 38°C 37 (58.7) 19 (90.5) 0.009
Fissuration/disruption 7 (11.1) 2 (9.5) 0.02
False aneurysm 9 (14.2) 2 (9.5) 0.6
White blood cells count (G/l) 11.196 ± 4.6 11.022 ± 3.48 0.88
Mean ± SD
Autologous vein 10 (15.8) 2 (9.5) 0.47
Arterial homo/allograft 20 (31.7) 4 (19) 0.26
New prosthesis 6 (9.5) 2 (9.5) 1
Debridement 16 (25.4) 8 (38.1) 0.26
Medical treatment (no surgery) 9 (9.5) 4 (19) 0.6
Adequate empirical antibiotherapy 60 (95.2) 19 (90.4) 0.42
New surgery 15 (23.8) 10 (47.6) 0.02
Rifampin combination 38 (60.3) 7 (33.3) 0.03
Admission to intensive care unit 21 (33.3) 14 (66.6) 0.007
Septic shock at initial presentation 7 (11.1) 8 (38.1) 0.005
Post-operative dialysis 0 (0) 4 (19) 0.001
Death related to PVGI 0 (0) 14 (66.6) 0.001
Death not related to PVGI 6 (9.5) 2 (9.5) 1
Median follow-up (interquartile) (days) 605 ± 406 621 ± 455 0.2
PVGI: Prosthetic vascular graft infection. MSSA: Methicillin-susceptible Staphylococcus aureus; MRSA: Methicillin-resistant Staphylococcus aureus; CNS,
Coagulase-negative staphylococci.
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Table 2 Demographic characteristics of patients treated with rifampin or non-rifampin regimen
Population, n = 84 NoRifampicin Rifampicin p
n = 39, (%) n = 45, (%)
Age, mean ± SD 68.59 ± 11.23 62.02 ± 10.93 0.006
Diabetes mellitus 10 (40.0%) 15 (60.0%) 0.441
Body mass index, mean ± SD 25.31 ± 4.28 25.72 ± 4.61 0.676
Creatinine clearance <60 ml/min 70.33 ± 31.95 86.07 ± 34.68 0.035
Immunodepression 5 (33.3%) 10 (66.7%) 0.261
Chronic obstructive pulmonary disease 11 (50.0%) 11 (50.0%) 0.15
Coronary disease 24 (50.0%) 24 (50.0%) 0.448
Aortic aneurysm 16 (50.0%) 16 (50.0%) 0.606
Presumed PVGI 1 (12.5%) 7 (87.5%) 0.043
Definite PVGI 38 (50.0%) 38 (50.0%) 0.043
Early definite PVGI (<4 months) 24 (57.1%) 18 (42.9%) 0.049
Late definite PVGI (> 4 months) 14 (41.2%) 20 (58.8%) 0.426
Extracavitary PVGI 19 (50.0%) 19 (50.0%) 0.550
Fever > 38°C 26 (46.4%) 30 (53.6%) 0.865
Fissuration/disruption 2 (22.2%) 7 (77.8%) 0.125
False aneurysm 7 (63.6) 4 (36.4) 0.209
White blood cells count (G/l) 11410.7 ± 4463.2 10882.1 ± 4162.3 0.0645
Mean ± SD
Autologous vein 9 (75.0%) 3 (25.0%) 0.032
Arterial homo/allograft 9 (37.5%) 15 (62.5%) 0.299
New prosthesis 4 (50.0%) 4 (50.0%) 0.831
Debridement 2 (50.0%) 2 (50.0%) 0.883
Medical treatment (no surgery) 5 (38.5%) 8 (61.5%) 0.531
Adequate empirical antibiotherapy 37 (46.8%) 42 (53.2%) 0.766
New surgery 9 (36.0%) 16 (64.0%) 0.165
Admission to intensive care unit 22 (62.9%) 13 (37.1%) 0.010
Septic shock at initial presentation 8 (53.3%) 7 (46.7%) 0.554
Post-operative dialysis 3 (75.0%) 1 (25.0%) 0.240
Death related to PVGI 11 (78.6%) 3 (21.4%) 0.008
Table 3 Microbiological datas from patients study treated for staphylococcal prosthetic vascular graft infection (PVGI)
according to the outcome
Population, n = 84 Remission Failure p
n = 63, (%) n = 21, (%)
Positive blood culture 23 (36.5) 12 (57.1) 0.09
Positive blood and intraoperative culture 13 (20.6) 8 (38.1) 0.11
Positive intraoperative culture 39 (61.9) 8 (38.1) 0.05
MSSA 35 (55.5) 13 (61.9) 0.61
MRSA 14 (22.2) 3 (14.3) 0.43
CNS 14 (22.2) 8 (38.1) 0.15
Polymicrobial PVGI 11 (17.4) 3 (14.3) 0.3
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including anti-MRSA agents combinations (linezolid-doxy-
cycline n = 1, daptomycin-piperacillin/tazobactam n = 1,
cotrimoxazole-fucidic acid (n = 1), teicoplanin-doxycycline
(n = 1), vancomycin-fosfomycin (n = 1), vancomycin-pipera-
cillin/tazobactam (n = 1), or including others combinations
(n = 7), either monotherapy [fluoroquinolone alone (n = 1),
linezolid (n = 2), doxycycline (n = 2), cotrimoxazole (n = 1).
Four patients continued their treatment with suppressive
therapy.
During the overall follow-up, twenty-two patients died in-
cluding 14 directly due to PVGI [mean of 21 days (1–32)].
The others died of cancer [mean of 33 months (14–48)].
After a mean post-treatment follow-up > 1 year, remis-
sion of infection was observed in 63 patients (75%)
(Figure 1). Twenty-one patients failed, most of whom had
to be admitted in intensive care unit at initial presentation.
In univariate analysis (Table 1), significant risk factors
associated with failure were renal failure (P = 0.04),
aortic aneurysm (P = 0.03), fever (P = 0.009), aneurysm
disruption (P = 0.02) and septic shock in the peri-operative
period (P = 0.005), whereas antibiotic treatment containing
RIF was associated with better outcome (P = 0.03).
In multivariate analysis, only 2 variables were inde-
pendently associated with failure: septic shock [OR 4.98:
CI 95% 1.45-16.99; P = 0.01] and antibiotic treatment
containing RIF [OR 0.32: CI 95% 0.10-0.96; P = 0.04].
The quality of the model has been evaluated through its
measures of sensibility and specificity with establishment
of ROC curve and measure of the area under the curve
who was 0.742.
The Kaplan meier estimates of cumulative failure free
period according to the treatment group was detailed on
Figure 2. The validity of the model was assessed with the
log rank test which was 0.039.
Discussion
We report the outcome of 84 patients treated for
staphylococcal PVGI. Remission was observed in 75% of





84 patients with a follow-up > 1 year 
7 excluded for absence of 
complete datas or insufficient 
follow-up
Definite PVGI : early (n=42), late 
(n=34)
Presumed PVGI (n=8)
Intracavitary PVGI : n=47
Extracavitary PVGI : n=37
Initial Surgical treatment: n=68 [autologous vein n=12, arterial homo/allograft    
n=24, new prosthesis (n=8), debridement (n=24)
Initial medical treatment : n=14
New surgery (n=25)
Adequate empirical treatment n=79
Death: directly related to PVGI : 
n=16
Failure n=21  (25%)
Remission n=63 (75%)
median length of follow-up: 470 ± 
469 days
Figure 1 Patients study treated for staphylococcal prosthetic vascular graft infection (PVGI).
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our patients despite adequate empirical antimicrobial
treatment most often associated with optimal surgery.
The results of the present study suggest that shock in
the peri-operative period at initial presentation, renal
failure, aortic aneurysm, fever and aneurysm disruption
are risk factors in failure. Conversely, methicillin resist-
ance and intracavitary PVGI were not associated with
worsened outcome.
In our previous study [3], 16/71 patients (22.5%)
treated for PVGI and who had minimum follow-up of
one year died from persistent, recurrent or new infec-
tion. Independent prognostic factors in in-hospital mor-
tality were: age > 70 years and aortic PVGI. Chalmers
et al. [30] found that MRSA was associated with poor
outcome. In the literature, other risk factors in failure
were identified, including conservative treatment [31],
partial graft preservation [32], reimplantation of a new
expanded tetrapolyfluoroethylen (ePTFE) prosthetic graft,
another operation [33], inappropriate antibiotic use, mycotic
aneurysm [12], Pseudomonas aeruginosa-related PVGI
[34] and thoracic localization [35]. These factors were
also associated with a high mortality rate, varying from
6 to 100%.
We also found that use of RIF combinations was asso-
ciated with improved outcome of staphylococcal PVGI
when compared to other antibiotic regimens, consistent
with results of previous studies on other device-related
infections such as those linked to orthopedic devices
[20,36,37] and prosthetic valvular endocarditis [17,38].
Use of RIF combinations in these infections is supported
by its intense and rapid bactericidal activity against
staphylococci, its ability to penetrate into the biofilm
and its persistent activity against microorganisms in sta-
tionary growth phase that are present at the surface of
infected implants, including vascular grafts [13-16].
In experimental vascular graft infection, Edmiston et al.
[14] investigated the activity of 6 antimicrobial agents (i.e.
linezolid, RIF, daptomycin, ceftriaxone, vancomycin and
gentamicin) against biofilm-forming and non-biofilm-
forming strains of staphylococci adhering to graft pros-
thetic surfaces. They suggested that bactericidal activity is
influenced by: (i) the composition and structural character-
istics of the biomedical device surface (i.e. Dacron or
ePTFE); (ii) the selective activity of the antimicrobial agent;
and (iii) the presence or absence of an exopolysaccharide
biofilm. Daptomycin, RIF, and linezolid demonstrated
greater efficacy and speed at eradicating the microbial
adherence of staphylococcal isolates in ePTFE infection
than in Dacron infection.
In clinical studies on PVGI, medical treatment was
heterogeneous in terms of the antimicrobial agents used,
use or not of combined antibiotic and duration and ad-
ministration of treatment, and was mainly based on the
physician’s experience [1,4,5,39]. The optimal choice of
Time analysis (days)
Number at risk at each time point:
(A) 7                                     5                                       3                                        1
(B) 11                                    2                                       0                                        0    
rifampin group (A) 
Group with no rifampin (B)
Figure 2 Kaplan–Meier estimates of cumulative failure-free period according to treatment group; (log rank test p = 0.039).
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antimicrobial agents in empirical or definitive therapy
and the duration of treatment of PVGI remain unclear.
Our results do not argue for including RIF in empirical
antibiotic regimens (i.e. before definitive microbiological
results are available). Indeed, RIF should only be pre-
scribed after definitive bacteriological documentation,
and should systematically be associated with another ef-
fective molecule, thereby reducing the risk of emergence
of RIF-resistant staphylococcus mutants. In the present
study, RIF was initiated in combination with another ac-
tive antistaphylococcal agent chosen on the basis of de-
finitive microbiological results. In addition, RIF was
begun only after all devices aimed at draining the surgi-
cal site had been removed, so as to reduce the risk of
selecting RIF-resistant mutants.
To our knowledge, the present study is the first to in-
clude patients with a homogenous definition of PVGI
and treated via homogenous approaches; moreover, we
performed long-term follow-up. The present study had
several limitations. Potential bias might reside in the var-
iety of surgical approaches, inclusion of aortic and limb
PVGI in the same analysis, the delay to surgical proced-
ure and, finally, selection of patients treated at a referral
center. Its’ the reason why we cannot firmly conclude
that rifampin is the only factor which improves the out-
come. The homogenous approach in the management of
these patients, the management in the peri-operative
period in operating theater and in the intensive care unit
are the key of the treatment of patients with PVGI.
Conclusion
In conclusion, use of RIF combination as targeted treat-
ment for staphylococcal PVGI based on reliable microbio-
logical documentation seems to be associated with
improved outcome of PVGI compared to other antibiotic
regimens. The present study suggests a novel example of
the advantage of RIF combinations administered under
optimal conditions for treatment of staphylococcal im-
plant infections.
Competing interest
Potential conflict of interest: LL has received travel grants from Pfizer and has
been a speaker for Novartis. ES has received travel grants from
Sanofi-Aventis, has participated in data monitoring boards for Merck Sharp
and Dohme-Chibret and has been a speaker for Novartis and Pfizer. OL has
received grants from Pfizer and has been speaker for Novartis. The others
authors declare they have no competing interest.
This work was presented in part at the 52nd ICAAC, San Francisco, CA, USA,
2012 (abstract A 1805) and received no financial support.
Authors’ contributions
LL: clinical data, data analysis, writing of manuscript; PD, BSB,CR, MM, SH:
clinical data, MV: statistical analysis, OL and ES: clinical data, data analysis,
readers. All authors read and approved the final manuscript.
Acknowledgement
We thank Jerri Bram for English assistance.
Author details
1Infectious Diseases Department, Dron Hospital of Tourcoing, Rue du
Président Coty, Tourcoing 59208, France. 2Intensive Care and Infectious
Diseases Unit, Dron Hospital of Tourcoing, Tourcoing, France. 3Department of
Vascular Surgery, Dron Hospital of Tourcoing, Tourcoing, France.
4Department of Vascular Surgery, University Hospital of Lille, Lille, France.
Received: 8 October 2013 Accepted: 12 March 2014
Published: 28 April 2014
References
1. FitzGerald SF, Kelly C, Humphreys H: Diagnosis and treatment of
prosthetic aortic graft infections: confusion and inconsistency in the
absence of evidence or consensus. J Antimicrob Chemother 2005,
56(6):996–999.
2. Yeager RA, McConnell DB, Sasaki TM, Vetto RM: Aortic and peripheral
prosthetic graft infection: differential management and causes of
mortality. Am J Surg 1985, 150(1):36–43.
3. Legout L, Sarraz-Bournet B, D’Elia PV, Devos P, Pasquet A, Caillaux M, Wallet
F, Yazdanpanah Y, Senneville E, Haulon S, Leroy O: Characteristics and
prognosis in patients with prosthetic vascular graft infection:
a prospective observational cohort study. Clin Microbiol Infect 2012,
18(4):352–358.
4. Darouiche RO: Treatment of infections associated with surgical implants.
N Engl J Med 2004, 350(14):1422–1429.
5. Gandelman G, Frishman WH, Wiese C, Green-Gastwirth V, Hong S, Aronow
WS, Horowitz HW: Intravascular device infections: epidemiology,
diagnosis, and management. Cardiol Rev 2007, 15(1):13–23.
6. Baddour LM, Bettmann MA, Bolger AF, Epstein AE, Ferrieri P, Gerber MA,
Gewitz MH, Jacobs AK, Levison ME, Newburger JW, Pallasch TJ, Wilson WR,
Baltimore RS, Falace DA, Shulman ST, Tani LY, Taubert KA: Nonvalvular
cardiovascular device-related infections. Circulation 2003, 108(16):2015–2031.
7. Kieffer E, Gomes D, Chiche L, Fleron MH, Koskas F, Bahnini A: Allograft
replacement for infrarenal aortic graft infection: early and late results in
179 patients. J Vasc Surg 2004, 39(5):1009–1017.
8. Gassel HJ, Klein I, Steger U, Kellersmann R, Hamelmann W, Franke S, Thiede
A: Surgical management of prosthetic vascular graft infection:
comparative retrospective analysis of 30 consecutive cases. Vasa 2002,
31(1):48–55.
9. Goeau-Brissonniere O, Mercier F, Nicolas MH, Bacourt F, Coggia M, Lebrault
C, Pechère JC: Treatment of vascular graft infection by in situ
replacement with a rifampin-bonded gelatin-sealed Dacron graft. J Vasc
Surg 1994, 19(4):739–741.
10. Blanch M, Berjon J, Vila R, Simeon JM, Romera A, Riera S, Cairols MA: The
management of aortic stent-graft infection: endograft removal versus
conservative treatment. Ann Vasc Surg 2010, 24(4):554. e1-5.
11. Mingoli A, Sapienza P, Feldhaus RJ, di Marzo L, Burchi C, Cavallaro A:
Aortoiliofemoral bypass graft in young adults: long-term results in a
series of sixty-eight patients. Surgery 1997, 121(6):646–653.
12. O’Connor S, Andrew P, Batt M, Becquemin JP: A systematic review and
meta-analysis of treatments for aortic graft infection. J Vasc Surg 2006,
44(1):38–45.
13. Smith K, Perez A, Ramage G, Gemmell CG, Lang S: Comparison of
biofilm-associated cell survival following in vitro exposure of
meticillin-resistant Staphylococcus aureus biofilms to the antibiotics
clindamycin, daptomycin, linezolid, tigecycline and vancomycin.
Int J Antimicrob Agents 2009, 33(4):374–378.
14. Edmiston CE Jr, Goheen MP, Seabrook GR, Johnson CP, Lewis BD, Brown KR,
Towne JB: Impact of selective antimicrobial agents on staphylococcal
adherence to biomedical devices. Am J Surg 2006, 192(3):344–354.
15. LaPlante KL, Woodmansee S: Activities of daptomycin and vancomycin
alone and in combination with rifampin and gentamicin against
biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an
experimental model of endocarditis. Antimicrob Agents Chemother 2009,
53(9):3880–3886.
16. Bayer AS, Lam K: Efficacy of vancomycin plus rifampin in experimental
aortic-valve endocarditis due to methicillin-resistant Staphylococcus
aureus: in vitro-in vivo correlations. J Infect Dis 1985, 151(1):157–165.
17. Riedel DJ, Weekes E, Forrest GN: Addition of rifampin to standard therapy
for treatment of native valve infective endocarditis caused by
Legout et al. BMC Infectious Diseases 2014, 14:228 Page 8 of 9
http://www.biomedcentral.com/1471-2334/14/228
Staphylococcus aureus. Antimicrob Agents Chemother 2008,
52(7):2463–2467.
18. Faville RJ Jr, Zaske DE, Kaplan EL, Crossley K, Sabath LD, Quie PG:
Staphylococcus aureus endocarditis. Combined therapy with
vancomycin and rifampin. JAMA 1978, 240(18):1963–1965.
19. Senneville E, Gaworowska D, Topolinski H, Devemy F, Nguyen S, Singer B,
Beltrand E, Legout L, Caillaux M, Descamps D, Canonne JP, Yazdanpanah Y:
Outcome of patients with diabetes with negative percutaneous bone
biopsy performed for suspicion of osteomyelitis of the foot. Diabet Med
2012, 29(1):56–61.
20. Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE: Role of rifampin for
treatment of orthopedic implant-related staphylococcal infections:
a randomized controlled trial. Foreign-Body Infection (FBI) Study Group.
JAMA 1998, 279(19):1537–1541.
21. Widmer AF, Gaechter A, Ochsner PE, Zimmerli W: Antimicrobial treatment
of orthopedic implant-related infections with rifampin combinations.
Clin Infect Dis 1992, 14(6):1251–1253.
22. Nguyen S, Pasquet A, Legout L, Beltrand E, Dubreuil L, Migaud H,
Yazdanpanah Y, Senneville E: Efficacy and tolerance of rifampicin-linezolid
compared with rifampicin-cotrimoxazole combinations in prolonged oral
therapy for bone and joint infections. Clin Microbiol Infect 2009,
15(12):1163–1169.
23. Legout L, D’Elia P, Devos P, Ettahar N, Sarraz-Bournet B, Haulon S, Senneville
E, Leroy O: Risk factors for methicillin-resistant staphylococcal vascular
graft infection in an 11-year cohort study. J Infect 2012, 64(4):441–444.
24. Roon AJ, Malone JM, Moore WS, Bean B, Campagna G: Bacteremic
infectability: a function of vascular graft material and design. J Surg Res
1977, 22(5):489–498.
25. Malone JM, Moore WS, Campagna G, Bean B: Bacteremic infectability of
vascular grafts: the influence of pseudointimal integrity and duration of
graft function. Surgery 1975, 78(2):211–216.
26. The Expert Committee on the Diagnosis and Classification of Diabetes
Mellitus: Report of the expert committee on the diagnosis and
classification of diabetes mellitus. Diabetes Care 1997,
20(7):1183–1197.
27. Celli BR, Snider GL, Heffner J, Tiep B, Ziment I, Make B, Braman S, Olsen G,
Phillips Y: Standards for the diagnosis and care of patients with chronic
obstructive pulmonary disease. American Thoracic Society. Am J Respir
Crit Care Med 1995, 152:S77–S121.
28. Garrow JS, Webster J: Quetelet’s index (W/H2) as a measure of fatness.
Int J Obes 1985, 9(2):147–153.
29. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate
method to estimate glomerular filtration rate from serum creatinine:
a new prediction equation. Modification of Diet in Renal Disease Study
Group. Ann Intern Med 1999, 130(6):461–470.
30. Chalmers RT, Wolfe JH, Cheshire NJ, Stansby G, Nicolaides AN, Mansfield AO,
Barrett SP: Improved management of infrainguinal bypass graft infection
with methicillin-resistant Staphylococcus aureus. Br J Surg 1999,
86(11):1433–1436.
31. Saleem BR, Meerwaldt R, Tielliu IF, Verhoeven EL, van den Dungen JJ,
Zeebregts CJ: Conservative treatment of vascular prosthetic graft
infection is associated with high mortality. Am J Surg 2010, 200(1):47–52.
32. Mirzaie M, Schmitto JD, Tirilomis T, Fatehpur S, Liakopoulos OJ, Teucher N,
Dörge H, Schöndube FA: Surgical management of vascular graft infection
in severely ill patients by partial resection of the infected prosthesis.
Eur J Vasc Endovasc Surg 2007, 33(5):610–613.
33. Reilly LM, Stoney RJ, Goldstone J, Ehrenfeld WK: Improved management of
aortic graft infection: the influence of operation sequence and staging.
J Vasc Surg 1987, 5(3):421–431.
34. Calligaro KD, Veith FJ, Schwartz ML, Savarese RP, DeLaurentis DA: Are
gram-negative bacteria a contraindication to selective preservation of
infected prosthetic arterial grafts? J Vasc Surg 1992, 16(3):337–345.
discussion 45–6.
35. Coselli JS, LeMaire SA, Conklin LD, Koksoy C, Schmittling ZC: Morbidity and
mortality after extent II thoracoabdominal aortic aneurysm repair.
Ann Thorac Surg 2002, 73(4):1107–1115. discussion 15–6.
36. Senneville E, Joulie D, Legout L, Valette M, Dezèque H, Beltrand E, Roselé B,
d'Escrivan T, Loïez C, Caillaux M, Yazdanpanah Y, Maynou C, Migaud H:
Outcome and predictors of treatment failure in total hip/knee prosthetic
joint infections due to Staphylococcus aureus. Clin Infect Dis 2011,
53(4):334–340.
37. Sendi P, Graber P, Zimmerli W: Risk factors associated with acute hip
prosthetic joint infections and outcome of treatment with a
rifampin-based regimen. Acta Orthop 2008, 79(3):454. author reply 5.
38. Perlroth J, Kuo M, Tan J, Bayer AS, Miller LG: Adjunctive use of rifampin for
the treatment of Staphylococcus aureus infections: a systematic review
of the literature. Arch Intern Med 2008, 168(8):805–819.
39. Leroy O, Meybeck A, Sarraz-Bournet B, D’Elia P, Legout L: Vascular graft
infections. Curr Opin Infect Dis 2012, 25(2):154–158.
doi:10.1186/1471-2334-14-228
Cite this article as: Legout et al.: Factors predictive of treatment failure
in staphylococcal prosthetic vascular graft infections: a prospective
observational cohort study: impact of rifampin. BMC Infectious Diseases
2014 14:228.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Legout et al. BMC Infectious Diseases 2014, 14:228 Page 9 of 9
http://www.biomedcentral.com/1471-2334/14/228
